Teligent’s (NASDAQ:TLGT) development partner has received a Complete Response Letter (CRL) from the FDA for its abbreviated new drug application (ANDA) for its first complex drug indicated for an orphan disease population.

In the letter, the FDA requested further information and raw data to support the ANDA.





READ SOURCE

READ  Innovent Biologics jumps 21% on Hong Kong debut

WHAT YOUR THOUGHTS

Please enter your comment!
Please enter your name here